Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle
Open Access

Kinetic Analysis of the Early Signaling Steps of the Human Chemokine Receptor CXCR4

Cristina Perpiñá-Viciano, Ali Işbilir, Aurélien Zarca, Birgit Caspar, Laura E. Kilpatrick, Stephen J. Hill, Martine J. Smit, Martin J. Lohse and Carsten Hoffmann
Molecular Pharmacology August 2020, 98 (2) 72-87; DOI: https://doi.org/10.1124/mol.119.118448
Cristina Perpiñá-Viciano
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, University of Jena, Jena, Germany (C.P.-V., C.H.); Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany (C.P.-V., A.I., M.J.L., C.H.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (A.I., M.J.L.); Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands (A.Z., M.J.S.); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Medical School, Queen’s Medical Centre, Nottingham, United Kingdom (B.C., L.E.K., S.J.H.); and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, The Midlands, United Kingdom (B.C., L.E.K., S.J.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Işbilir
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, University of Jena, Jena, Germany (C.P.-V., C.H.); Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany (C.P.-V., A.I., M.J.L., C.H.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (A.I., M.J.L.); Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands (A.Z., M.J.S.); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Medical School, Queen’s Medical Centre, Nottingham, United Kingdom (B.C., L.E.K., S.J.H.); and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, The Midlands, United Kingdom (B.C., L.E.K., S.J.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurélien Zarca
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, University of Jena, Jena, Germany (C.P.-V., C.H.); Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany (C.P.-V., A.I., M.J.L., C.H.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (A.I., M.J.L.); Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands (A.Z., M.J.S.); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Medical School, Queen’s Medical Centre, Nottingham, United Kingdom (B.C., L.E.K., S.J.H.); and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, The Midlands, United Kingdom (B.C., L.E.K., S.J.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgit Caspar
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, University of Jena, Jena, Germany (C.P.-V., C.H.); Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany (C.P.-V., A.I., M.J.L., C.H.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (A.I., M.J.L.); Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands (A.Z., M.J.S.); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Medical School, Queen’s Medical Centre, Nottingham, United Kingdom (B.C., L.E.K., S.J.H.); and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, The Midlands, United Kingdom (B.C., L.E.K., S.J.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura E. Kilpatrick
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, University of Jena, Jena, Germany (C.P.-V., C.H.); Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany (C.P.-V., A.I., M.J.L., C.H.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (A.I., M.J.L.); Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands (A.Z., M.J.S.); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Medical School, Queen’s Medical Centre, Nottingham, United Kingdom (B.C., L.E.K., S.J.H.); and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, The Midlands, United Kingdom (B.C., L.E.K., S.J.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen J. Hill
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, University of Jena, Jena, Germany (C.P.-V., C.H.); Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany (C.P.-V., A.I., M.J.L., C.H.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (A.I., M.J.L.); Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands (A.Z., M.J.S.); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Medical School, Queen’s Medical Centre, Nottingham, United Kingdom (B.C., L.E.K., S.J.H.); and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, The Midlands, United Kingdom (B.C., L.E.K., S.J.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine J. Smit
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, University of Jena, Jena, Germany (C.P.-V., C.H.); Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany (C.P.-V., A.I., M.J.L., C.H.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (A.I., M.J.L.); Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands (A.Z., M.J.S.); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Medical School, Queen’s Medical Centre, Nottingham, United Kingdom (B.C., L.E.K., S.J.H.); and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, The Midlands, United Kingdom (B.C., L.E.K., S.J.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martine J. Smit
Martin J. Lohse
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, University of Jena, Jena, Germany (C.P.-V., C.H.); Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany (C.P.-V., A.I., M.J.L., C.H.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (A.I., M.J.L.); Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands (A.Z., M.J.S.); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Medical School, Queen’s Medical Centre, Nottingham, United Kingdom (B.C., L.E.K., S.J.H.); and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, The Midlands, United Kingdom (B.C., L.E.K., S.J.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carsten Hoffmann
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, University of Jena, Jena, Germany (C.P.-V., C.H.); Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany (C.P.-V., A.I., M.J.L., C.H.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (A.I., M.J.L.); Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands (A.Z., M.J.S.); Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Medical School, Queen’s Medical Centre, Nottingham, United Kingdom (B.C., L.E.K., S.J.H.); and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, The Midlands, United Kingdom (B.C., L.E.K., S.J.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Principle and functional characterization of the CXCR4-FlAsH228-CFP sensor. (A) Schematic depicting the intramolecular FRET-based sensor. Ligand-induced conformational changes in CXCR4 are monitored as changes in FRET. (B) Representative confocal images of HEK293 cells transiently expressing CXCR4-FlAsH228-CFP and FlAsH-labeled prior to the measurement. Upper panel shows CFP emission. Lower panel shows FlAsH emission. Scale bar, 10 µm. (C) Intramolecular FRET efficiency of CXCR4-FlAsH228-CFP as determined by BAL treatment. Values were calculated from the increase in the CFP fluorescence upon BAL addition. Data shows mean ± S.D. of 20 cells measured on 4 independent experimental days. A representative individual experiment is shown in Supplemental Fig. 2. (D) Gi1 activation via CXCR4 or CXCR4-FlAsH228 in response to increasing concentrations of CXCL12. Data show mean ± S.E.M. and are representative of n = 3 independent experiments conducted in quadruplicate. In this particular experiment, EC50 = 3.3 and 14.7 nM for CXCR4 and CXCR4-FlAsH228, respectively. (E) Inhibition of FSK-induced cAMP accumulation in response to increasing concentrations of CXCL12 by HEK293T cells expressing CXCR4, CXCR4-CFP, or CXCR4-FlAsH228-CFP. Data show mean ± S.E.M. and are representative of n = 4 independent experiments conducted in triplicate. In this particular experiment, EC50 = 7.3, 11.3, and 39.0 nM for CXCR4, CXCR4-CFP, and CXCR4-FlAsH228-CFP, respectively. Characterization of the CXCR4-FlAsH226-CFP and CXCR4-FlAsH229-CFP sensors is presented in Supplemental Fig. 1. RLU, relative light unit.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    The CXCR4-FlAsH228-CFP sensor reports the dynamics and kinetics of receptor activation and deactivation. (A and B) Representative traces of the FRET response from a single HEK293 cell expressing the CXCR4-FlAsH228-CFP sensor and stimulated with 30 µM CXCL12 for the indicated period of time (black line). Left panel shows corrected and normalized FRET ratio. Right panel shows corrected FlAsH (yellow) and CFP (cyan) emissions. (C) Kinetic analysis of receptor activation. The FRET change was fitted to a one-component exponential decay function to obtain the time constant τ. (D and E) On-kinetics of CXCR4 in response to CXCL12 (D) and off-kinetics of CXCR4 upon wash-out of the ligand with buffer (E). τ values from individual experiments are represented in a scatter plot. Data show median and IQR of 17 cells measured on 4 independent experimental days. a.u., arbitrary units.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    CXCL12 induces rearrangements between CXCR4 and the Gi1 protein. (A and B) Schematic depicting the settings employed to investigate the interaction between the receptor and the Gi1 protein. HEK293 cells were transfected with CXCR4-YFP and Gαi1/Gβ1/Gγ2-CFP (A) or Gαi1-CFP/Gβ1/Gγ2 (B). (C and D) Representative traces of the FRET response from a single HEK293 cell expressing CXCR4-YFP and the G protein CFP-labeled at the Gγ2 (C) or Gαi1 subunit (D) and stimulated with 30 µM CXCL12 for the indicated period of time (black line). Upper panels show corrected YFP (yellow) and CFP (cyan) emissions. Lower panels show corrected and normalized FRET ratios. (E) On-kinetics of the interaction of CXCR4 with the Gi1 protein upon CXCL12 stimulation as measured in the two settings. τ values from individual experiments are represented in a scatter plot. Data show median and IQR of 12 cells for each setting, measured on at least 3 independent experimental days. Statistical significance was tested using Mann-Whitney test. a.u.,arbitrary units; n.s., nonsignificant.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    CXCR4 resides within FRET distance from Gi proteins in the absence of agonist. (A) Schematic of acceptor photobleaching experiments. Donor and acceptor emissions were measured prior to and after photobleaching the YFP in HEK293 cells expressing the constructs Gαi1/Gβ1/Gγ2-CFP and α2A-AR-YFP or CXCR4-YFP. The latter was also measured in the presence of IT1t. (B) The change in the FCFP after YFP photobleaching from individual experiments in each condition is shown as a box plot. N = 19, 13, and 12 cells for CXCR4, CXCR4 + IT1t, and α2A-AR, respectively, measured on 3 independent experimental days. Statistical significance was tested using unpaired t test (***P ≤ 0.001; ****P ≤ 0.0001). (C–E) Representative CFP (cyan) and YFP (yellow) traces from individual experiments. The YFP photobleaching period is indicated in gray. a.u., arbitrary units.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    CXCR4 activates Gi proteins in response to CXCL12. (A) FRET-based sensors for Gi1, Gi2, Gi3, and Gq were employed to study G protein activation. A loss of FRET between the Gγ-Venus and Gα-mTurquoise2 subunits is detected upon activation. (B and C) Representative traces of the FRET response from a single HEK293 cell expressing the Gi2 sensor and CXCR4 (B) or α2A-AR (C) and stimulated with 30 μM CXCL12 or 100 µM norepinephrine, respectively (black line). Upper panels show corrected Venus (yellow) and mTurquoise2 (cyan) emissions. Lower panels show corrected and normalized FRET ratios. Supplemental Fig. 3 shows activation of Gi1 and Gi3. (D) Kinetics of Gi1, Gi2, and Gi3 protein activation via CXCR4 or α2A-AR in response to CXCL12 and norepinephrine, respectively. Table shows median and IQR. τ values from individual experiments are represented in a scatter plot with median and IQR. For CXCR4, n = 11, 22, and 11 cells for Gi1, Gi2, and Gi3 activation, respectively, measured on at least 3 independent experimental days. For α2A-AR, n = 17, 16, and 7 cells for Gi1, Gi2, and Gi3 activation, respectively, measured on at least 2 independent experimental days. Statistical significance was tested using Kruskal-Wallis test. n.s., nonsignificant. (E) CXCR4-mediated activation of Gi1, Gi2, Gi3, and Gq activation in response to increasing concentrations of CXCL12. As a control, empty plasmid was transfected instead of receptor. Data show mean ± S.E.M. and are representative of n = 5 independent experiments conducted in quadruplicate. In this particular experiment, EC50 values were 9.7, 10.8, and 17.1 nM for Gi1, Gi2, and Gi3, respectively. (F) FRET of cells expressing the CXCR4 and Gi2 sensor upon treatment with buffer, buffer supplemented with 100 µM IT1t or 100 nM CXCL12. Data are representative of three independent experiments. Data show mean ± S.D. and are normalized to buffer treatment. N = 30, 30, and 15 wells (containing 15,000 cells each) for the treatment with buffer, IT1t, and CXCL12, respectively. Statistical significance was tested using unpaired t test (**P ≤ 0.01; ****P ≤ 0.0001). a.u., arbitrary units.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    CXCR4 homodimers undergo conformational changes in response to CXCL12. (A) The rearrangement between CXCR4 protomers was investigated in HEK293 cells cotransfected with CXCR4-CFP and CXCR4-YFP, with the fluorophores fused to the C termini. (B) Representative traces of the FRET response from a single HEK293 cell expressing CXCR4-YFP and CXCR4-CFP and stimulated with 30 μM CXCL12 (black line). Upper panel shows corrected YFP (yellow) and CFP (cyan) emissions. Lower panel shows corrected and normalized FRET ratio. (C and D) On-kinetics of the rearrangement between CXCR4 protomers in response to CXCL12 (C) and off-kinetics upon wash-out of the ligand with buffer (D). τ alues from individual experiments are represented in a scatter plot with median and IQR. N = 28 and 10 cells, respectively, measured on 4 independent experimental days. a.u., arbitrary units.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    MIF induces structural rearrangements in CXCR4 but does not lead to Gi protein activation. (A, C, E, and G) Representative traces of the FRET response from a single HEK293 cell transiently expressing: CXCR4-FlAsH228-CFP sensor (A), CXCR4-YFP and Gαi1/Gβ1/Gγ2-CFP (C), CXCR4-CFP and CXCR4-YFP (E) or CXCR4 and Gi2 sensor (G), which were stimulated with 100 µM MIF and then followed by wash-out and then stimulation with 30 μM CXCL12. Upper panels show corrected acceptor (yellow) and donor (cyan) emissions. Lower panels show corrected and normalized FRET ratios. (B, D, and F) On-kinetics of receptor activation (n = 9 cells) (B), receptor/G protein interaction (n = 13 cells) (D) and rearrangement between CXCR4 protomers (n = 17 cells) (F) in response to 100 µM MIF. τ values from individual experiments are represented in a scatter plot with median and IQR. Measurements were performed on at least 2 independent experimental days. (H) Comparison of CXCR4 on-kinetics in response to CXCL12 and MIF. Data from receptor activation belong to Figs. 2D and 7B. Data from receptor/G protein interaction belong to Figs. 3E (Gγ-labeled) and 7D. Data from protomers rearrangement belong to Figs. 6C and 7F. Data from G protein activation belong to Fig. 5D (Gi2 sensor). Data are shown as a box plot in which the whiskers represent maximum and minimum values. a.u., arbitrary units.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Summary of the findings in this manuscript regarding the CXCL12/CXCR4 axis. The upper part of the figure shows the kinetics of each step of the signaling cascade investigated using FRET. The main findings regarding the CXCL12/CXCR4 axis are: 1) Activation kinetics of CXCR4 upon CXCL12 binding are slower than other class A GPCRs; 2) Rearrangements within dimers occur faster than activation of Gi proteins; 3) This axis leads to a prolonged activation of Gi proteins; and 4) CXCR4 exhibits some degree of constitutive activity. It is tempting to speculate that the rearrangement between protomers precedes G protein activation, which might suggest that conformational changes in CXCR4 homodimers, when present, play a possible role in the signaling activation course of this receptor as depicted in model B. However, we need to emphasize that mechanistic interpretation needs to be based on measuring microscopic rate constants, and hence, model A, in which the dimer rearrangement offers an alternative pathway, is also compatible with our dataset. a.u., arbitrary units.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Figures -

      Supplementary Figure 1 - Characterization of the CXCR4-FlAsH226-CFP and CXCR4-FlAsH229-CFP sensors.

      Supplementary Figure 2 - Determination of the intra- and intermolecular FRET efficiency of the CXCR4-FlAsH228-CFP sensor.

      Supplementary Figure 3 - Activation of Gi1 and Gi3 via CXCR4 or α2A-AR upon stimulation with their respective ligands, CXCL12 and norepinephrine.

      Supplementary Figure 4 - CXCL12-induced CXCR4 responses are not affected by prior stimulation of the cells with MIF.

      Supplementary Figure 5 - Competition of CXCL12 with MIF for binding to CXCR4.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 98 (2)
Molecular Pharmacology
Vol. 98, Issue 2
1 Aug 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Kinetic Analysis of the Early Signaling Steps of the Human Chemokine Receptor CXCR4
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Early Steps in the Activation Mechanism of CXCR4

Cristina Perpiñá-Viciano, Ali Işbilir, Aurélien Zarca, Birgit Caspar, Laura E. Kilpatrick, Stephen J. Hill, Martine J. Smit, Martin J. Lohse and Carsten Hoffmann
Molecular Pharmacology August 1, 2020, 98 (2) 72-87; DOI: https://doi.org/10.1124/mol.119.118448

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Early Steps in the Activation Mechanism of CXCR4

Cristina Perpiñá-Viciano, Ali Işbilir, Aurélien Zarca, Birgit Caspar, Laura E. Kilpatrick, Stephen J. Hill, Martine J. Smit, Martin J. Lohse and Carsten Hoffmann
Molecular Pharmacology August 1, 2020, 98 (2) 72-87; DOI: https://doi.org/10.1124/mol.119.118448
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics